Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    127
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DD04 TRIAXONE G Ceftriaxone (sodium) - 500mg 500mg Injectable powder for solution+diluent 356,118 L.L
J01XA01 VANCOLON G Vancomycin (HCl) - 0.5g 0.5g Injectable lyophilised powder for solution 1,009,226 L.L
L01AX03 TEMOZOLOMIDE GP PHARM G Temozolomide - 250mg 250mg Capsule, hard 12,058,004 L.L
L04AA27 PMS-FINGOLIMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule 19,351,580 L.L
N06AB06 SERTRALINE BIOGARAN G Sertraline HCl - 25mg 25mg Capsule 130,353 L.L
R02A TRACHISAN G Lidocaine HCl - 1mg, Tyrothricin - 0.5mg, Chlorhexidine gluconate - 1mg Lozenge 228,453 L.L
R06AX13 LORATIN G Loratadine (micronised) - 10mg 10mg Tablet 247,267 L.L
L01CD04 CABAZITAXEL EVER PHARMA G Cabazitaxel - 60mg/6ml 10mg/ml Injectable concentrate for solution L.L
A11DB TRILAGAVIT G Vitamin B12 - 1mg/3ml, Vitamin B6 - 100mg/3ml, Vitamin B1 - 100mg/3ml Injectable solution 579,196 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 163,184 L.L
C07AB07 B-COR 5 G Bisoprolol fumarate - 5mg 5mg Tablet, film coated 296,989 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet 579,196 L.L
D11AX01 HAIRGAINE 5 G Minoxidil - 5% 5% Solution 1,963,354 L.L
J01XA01 VANCOMYCIN HIKMA G Vancomycin (HCl) - 500mg 500mg Injectable powder for solution 998,475 L.L
L01AX03 TEMOZOLOMIDE PHARMINICIO G Temozolomide - 250mg 250mg Capsule, hard 12,058,004 L.L
L04AA27 SCLEMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule 18,264,981 L.L
M01AE17 DEXKEVITAE G Dexketoprofen (trometamol) - 25mg 25mg Tablet, film coated 486,471 L.L
N02AX02 MABRON G Tramadol HCl - 100mg/2ml 100mg/2ml Injectable solution 146,479 L.L
N03AX18 TREPADIO G Lacosamide - 150mg 150mg Tablet, film coated 7,555,604 L.L
R02A CHLORASEPTIC TOTAL SORE THROAT + COUGH LOZENGES WILD CHERRY G Benzocaine - 6mg, Dextromethorphan - 5mg, Menthol - 10mg Lozenge 537,537 L.L
R06AX13 LORINE G Loratadine (micronised) - 10mg 10mg Tablet 247,267 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 1mg 1mg Tablet, coated L.L
A11DB VITANOR G Vitamin B1 - 250mg, Vitamin B6 - 250mg, Vitamin B12 - 500mcg Tablet, film coated 946,065 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 156,288 L.L
C07AB07 BISCORDEX G Bisoprolol fumarate - 5mg 5mg Tablet 406,992 L.L
C09DA03 VIOSTAN PLUS 160/25 G Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet, film coated 671,921 L.L
D11AX01 HAIRGROW G Minoxidil - 5% 5% Solution 1,061,636 L.L
J01XA01 VANCOMYCINE VIATRIS 500MG G Vancomycin - 500mg 500mg Injectable dry powder for solution 885,115 L.L
L04AA27 SCLEMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule 17,079,643 L.L
M01AE17 DEXON G Dexketoprofen - 25mg 25mg Tablet, film coated 239,204 L.L
    ...
    127
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025